39762936|t|Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease.
39762936|a|BACKGROUND: Fluoroethylnormemantine (FENM), a new Memantine (MEM) derivative, prevented amyloid-beta[25-35] peptide (Abeta25-35)-induced neurotoxicity in mice, a pharmacological model of Alzheimer's disease (AD) with high predictive value for drug discovery. Here, as drug infusion is likely to better reflect drug bioavailability due to the interspecies pharmacokinetics variation, we analyzed the efficacy of FENM after chronic subcutaneous (SC) infusion, in comparison with IP injections in two AD mouse models, Abeta25-35-injected mice and the transgenic APPswe/PSEN1 E9 (APP/PS1) line. METHODS: In Abeta25-35-treated mice, FENM was infused at 0.03-0.3 mg/kg/day during one week after Abeta25-35 injection. For comparison, FENM and MEM were administered IP daily at 0.03-0.3 mg/kg. In 10-month-old APP/PS1 mice, FENM was administered during four weeks by daily IP injections at 0.3 mg/kg or chronic SC infusion at 0.1 mg/kg/day. Memory deficits, spatial working memory and recognition memory, were analysed. Markers of neuroinflammation, apoptosis, oxidative stress, and amyloid burden in APP/PS1 mice, were quantified. Markers of synaptic plasticity such as PSD-95 and GluN2A/B/D subunits expression in hippocampus homogenates or synaptosomes were quantified in Abeta25-35-treated mice and synaptic long-term potentiation (LTP) in hippocampal slices was analysed in APP/PS1 mice. RESULTS: Deficits in spontaneous alternation and object recognition in Abeta25-35 mice were prevented by infused FENM at all doses tested. Similar effects were observed with the daily FENM or MEM treatments. Animals infused with 0.1 mg/kg/day FENM showed prevention of Abeta25-35-induced neuroinflammation, oxidative stress and apoptosis. FENM infusion restored Abeta25-35-induced alterations in synaptosomal PSD-95, GluN2A and P-GluN2B levels. GluN2D levels were unchanged whatever the treatment. In APP/PS1 mice, FENM infused or administered IP alleviated spontaneous alternation deficits, neuroinflammation, increases in Abeta1-40/Abeta1-42 and hippocampal LTP alteration. CONCLUSION: These data confirmed the neuroprotective potential of FENM in the pharmacological Abeta25-35 and transgenic APP/PS1 mouse models of AD, with a superiority to MEM, and showed that the drug can be efficiently infused chronically.
39762936	45	68	Fluoroethylnormemantine	Chemical	MESH:C000606130
39762936	70	74	FENM	Chemical	MESH:C000606130
39762936	79	84	mouse	Species	10090
39762936	95	114	Alzheimer's disease	Disease	MESH:D000544
39762936	128	151	Fluoroethylnormemantine	Chemical	MESH:C000606130
39762936	153	157	FENM	Chemical	MESH:C000606130
39762936	166	175	Memantine	Chemical	MESH:D008559
39762936	177	180	MEM	Chemical	MESH:D008559
39762936	204	231	amyloid-beta[25-35] peptide	Chemical	-
39762936	233	243	Abeta25-35	Chemical	-
39762936	253	266	neurotoxicity	Disease	MESH:D020258
39762936	270	274	mice	Species	10090
39762936	303	322	Alzheimer's disease	Disease	MESH:D000544
39762936	324	326	AD	Disease	MESH:D000544
39762936	527	531	FENM	Chemical	MESH:C000606130
39762936	614	616	AD	Disease	MESH:D000544
39762936	617	622	mouse	Species	10090
39762936	631	641	Abeta25-35	Chemical	-
39762936	651	655	mice	Species	10090
39762936	696	699	PS1	Gene	19164
39762936	719	729	Abeta25-35	Chemical	-
39762936	738	742	mice	Species	10090
39762936	744	748	FENM	Chemical	MESH:C000606130
39762936	805	815	Abeta25-35	Chemical	-
39762936	843	847	FENM	Chemical	MESH:C000606130
39762936	852	855	MEM	Chemical	MESH:D008559
39762936	922	925	PS1	Gene	19164
39762936	926	930	mice	Species	10090
39762936	932	936	FENM	Chemical	MESH:C000606130
39762936	1049	1064	Memory deficits	Disease	MESH:D008569
39762936	1139	1156	neuroinflammation	Disease	MESH:D000090862
39762936	1191	1198	amyloid	Disease	MESH:C000718787
39762936	1213	1216	PS1	Gene	19164
39762936	1217	1221	mice	Species	10090
39762936	1279	1285	PSD-95	Gene	13385
39762936	1383	1393	Abeta25-35	Chemical	-
39762936	1402	1406	mice	Species	10090
39762936	1491	1494	PS1	Gene	19164
39762936	1495	1499	mice	Species	10090
39762936	1572	1582	Abeta25-35	CellLine	CVCL:A1DA
39762936	1583	1587	mice	Species	10090
39762936	1614	1618	FENM	Chemical	MESH:C000606130
39762936	1685	1689	FENM	Chemical	MESH:C000606130
39762936	1693	1696	MEM	Chemical	MESH:D008559
39762936	1744	1748	FENM	Chemical	MESH:C000606130
39762936	1770	1780	Abeta25-35	Chemical	-
39762936	1789	1806	neuroinflammation	Disease	MESH:D000090862
39762936	1840	1844	FENM	Chemical	MESH:C000606130
39762936	1863	1873	Abeta25-35	Chemical	-
39762936	1910	1916	PSD-95	Gene	13385
39762936	1918	1924	GluN2A	Gene	14811
39762936	1931	1937	GluN2B	Gene	14812
39762936	1946	1952	GluN2D	Gene	14814
39762936	2006	2009	PS1	Gene	19164
39762936	2010	2014	mice	Species	10090
39762936	2016	2020	FENM	Chemical	MESH:C000606130
39762936	2093	2110	neuroinflammation	Disease	MESH:D000090862
39762936	2243	2247	FENM	Chemical	MESH:C000606130
39762936	2271	2281	Abeta25-35	Chemical	-
39762936	2301	2304	PS1	Gene	19164
39762936	2305	2310	mouse	Species	10090
39762936	2321	2323	AD	Disease	MESH:D000544
39762936	2347	2350	MEM	Chemical	MESH:D008559
39762936	Negative_Correlation	MESH:C000606130	MESH:D000544
39762936	Negative_Correlation	MESH:C000606130	MESH:D008569
39762936	Comparison	MESH:C000606130	MESH:D008559
39762936	Negative_Correlation	MESH:C000606130	MESH:D020258

